MECOM and acute myeloid leukemia: This review aims to delineate the pathobiology of AML with MECOM rearrangements, evaluate current therapeutic strategies in the context of concomitant cytogenetic and molecular abnormalities, and present our treatment perspective while highlighting future directions for the management of this rare AML subtype.